Laboratorios Farmaceuticos Rovi Stock Net Income
| LABFF Stock | USD 90.61 0.00 0.00% |
In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Laboratorios Farmaceuticos, as well as the relationship between them.
Laboratorios Farmaceuticos' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Laboratorios Farmaceuticos' valuation are provided below:Laboratorios Farmaceuticos Rovi does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Laboratorios |
Laboratorios Farmaceuticos 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Laboratorios Farmaceuticos' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Laboratorios Farmaceuticos.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Laboratorios Farmaceuticos on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Laboratorios Farmaceuticos Rovi or generate 0.0% return on investment in Laboratorios Farmaceuticos over 90 days. Laboratorios Farmaceuticos is related to or competes with ALK-Abelló A/S, Genscript Biotech, Shanghai Junshi, Camurus AB, InnoCare Pharma, Siegfried Holding, and Zealand Pharma. Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical produ... More
Laboratorios Farmaceuticos Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Laboratorios Farmaceuticos' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Laboratorios Farmaceuticos Rovi upside and downside potential and time the market with a certain degree of confidence.
Laboratorios Farmaceuticos Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Laboratorios Farmaceuticos' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Laboratorios Farmaceuticos' standard deviation. In reality, there are many statistical measures that can use Laboratorios Farmaceuticos historical prices to predict the future Laboratorios Farmaceuticos' volatility.Laboratorios Farmaceuticos Backtested Returns
We have found three technical indicators for Laboratorios Farmaceuticos, which you can use to evaluate the volatility of the firm. The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Laboratorios Farmaceuticos are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Laboratorios Farmaceuticos Rovi has no correlation between past and present. Overlapping area represents the amount of predictability between Laboratorios Farmaceuticos time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Laboratorios Farmaceuticos price movement. The serial correlation of 0.0 indicates that just 0.0% of current Laboratorios Farmaceuticos price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Laboratorios Farmaceuticos Rovi reported net income of 153.08 M. This is 55.15% lower than that of the Healthcare sector and 118.54% higher than that of the Biotechnology industry. The net income for all United States stocks is 73.19% higher than that of the company.
Laboratorios Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Laboratorios Farmaceuticos' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Laboratorios Farmaceuticos could also be used in its relative valuation, which is a method of valuing Laboratorios Farmaceuticos by comparing valuation metrics of similar companies.Laboratorios Farmaceuticos is currently under evaluation in net income category among its peers.
Laboratorios Fundamentals
| Return On Equity | 0.39 | |||
| Return On Asset | 0.18 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 1.93 B | |||
| Shares Outstanding | 51.32 M | |||
| Shares Owned By Insiders | 60.25 % | |||
| Shares Owned By Institutions | 17.46 % | |||
| Price To Earning | 15.16 X | |||
| Price To Book | 6.51 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 648.68 M | |||
| Gross Profit | 379.83 M | |||
| EBITDA | 204.66 M | |||
| Net Income | 153.08 M | |||
| Cash And Equivalents | 158.94 M | |||
| Cash Per Share | 2.98 X | |||
| Total Debt | 52.52 M | |||
| Debt To Equity | 0.18 % | |||
| Current Ratio | 1.77 X | |||
| Book Value Per Share | 8.28 X | |||
| Cash Flow From Operations | 149.44 M | |||
| Earnings Per Share | 3.37 X | |||
| Number Of Employees | 1.75 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 2.62 B | |||
| Total Asset | 732.68 M | |||
| Z Score | 29.4 | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 732.68 M |
About Laboratorios Farmaceuticos Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Laboratorios Farmaceuticos Rovi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Laboratorios Farmaceuticos using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Laboratorios Farmaceuticos Rovi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Laboratorios Pink Sheet
Laboratorios Farmaceuticos financial ratios help investors to determine whether Laboratorios Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Laboratorios with respect to the benefits of owning Laboratorios Farmaceuticos security.